Search research articles
Contact Us
Filters
Showing results (41-50 of 75) with videos related to
Page
of 8
Sort By:
Expert Opinion on Biological Therapy
|
June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Dermatology and Therapy
|
June 5, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis
Luigi Gargiulo, Antonio Costanzo, Piergiorgio Malagoli, et al.
Frontiers in Medicine
|
July 20, 2023
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology
|
April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
European Journal of Dermatology : EJD
|
March 2, 2021
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
Andrea Chiricozzi, Antonio Costanzo, Maria Concetta Fargnoli, et al.
Clinical and Experimental Dermatology
|
January 13, 2026
Long-Term Effectiveness of Bimekizumab in Plaque Psoriasis: Two-Year Drug Survival from a Real-Life Multicenter Italian Study
Eleonora De Luca, Annunziata Dattola, Fabio Artosi, et al.
Journal of Clinical Medicine
|
January 23, 2024
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of Clinical Medicine
|
June 12, 2026
Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis)
Martina Burlando, Lidia Sacchelli, Alberta Bettacchi, et al.
Dermatology and Therapy
|
June 9, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study
Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 75) with videos related to
Sort By:
Page
of 8
Expert Opinion on Biological Therapy
|
June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Dermatology and Therapy
|
June 5, 2026
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis
Luigi Gargiulo, Antonio Costanzo, Piergiorgio Malagoli, et al.
Frontiers in Medicine
|
July 20, 2023
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology
|
April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
European Journal of Dermatology : EJD
|
March 2, 2021
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
Andrea Chiricozzi, Antonio Costanzo, Maria Concetta Fargnoli, et al.
Clinical and Experimental Dermatology
|
January 13, 2026
Long-Term Effectiveness of Bimekizumab in Plaque Psoriasis: Two-Year Drug Survival from a Real-Life Multicenter Italian Study
Eleonora De Luca, Annunziata Dattola, Fabio Artosi, et al.
Journal of Clinical Medicine
|
January 23, 2024
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of Clinical Medicine
|
June 12, 2026
Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis)
Martina Burlando, Lidia Sacchelli, Alberta Bettacchi, et al.
Dermatology and Therapy
|
June 9, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study
Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Page
of 8